Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKLINASDAQ:CVRXNASDAQ:LUNGNASDAQ:ZJYL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKLIAkili$0.43$0.43$0.19▼$1.25$34.01M1.722.20 million shsN/ACVRXCVRx$6.34+2.4%$8.68$4.30▼$18.55$165.30M1.39332,681 shs501,346 shsLUNGPulmonx$3.43+0.3%$5.50$3.18▼$9.37$138.09M0.65313,528 shs233,459 shsZJYLJin Medical International$0.80-3.4%$0.79$0.56▼$4.38$124.78M12.24296,013 shs167,953 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKLIAkili0.00%0.00%0.00%0.00%-0.16%CVRXCVRx0.00%+34.89%+1.44%-57.99%-21.34%LUNGPulmonx0.00%+1.18%-24.12%-50.79%-63.20%ZJYLJin Medical International0.00%-3.96%-15.20%-7.32%-76.56%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKLIAkiliN/AN/AN/AN/AN/AN/AN/AN/ACVRXCVRx2.8928 of 5 stars3.42.00.00.02.74.20.6LUNGPulmonx3.5639 of 5 stars4.43.00.00.02.92.50.6ZJYLJin Medical InternationalN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKLIAkili 0.00N/AN/AN/ACVRXCVRx 2.71Moderate Buy$14.50128.71% UpsideLUNGPulmonx 2.78Moderate Buy$12.07251.94% UpsideZJYLJin Medical International 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest AKLI, CVRX, LUNG, and ZJYL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025CVRXCVRxPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$20.00 ➝ $12.005/9/2025CVRXCVRxJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Underweight$15.00 ➝ $7.005/1/2025LUNGPulmonxCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $15.005/1/2025LUNGPulmonxPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$10.00 ➝ $9.005/1/2025LUNGPulmonxD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.004/8/2025CVRXCVRxLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$19.00 ➝ $14.004/8/2025CVRXCVRxCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$23.00 ➝ $18.003/10/2025LUNGPulmonxJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy3/10/2025LUNGPulmonxMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageEqual Weight ➝ Equal Weight3/10/2025LUNGPulmonxCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral ➝ Buy3/10/2025LUNGPulmonxD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$17.00 ➝ $17.00(Data available from 5/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKLIAkili$1.95M17.46N/AN/A$0.75 per share0.58CVRXCVRx$52.87M3.13N/AN/A$2.73 per share2.32LUNGPulmonx$87.47M1.58N/AN/A$3.09 per share1.11ZJYLJin Medical International$23.50M5.31$0.03 per share31.44$0.18 per share4.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKLIAkili-$59.49M-$0.61N/AN/AN/A-2,492.04%-79.93%-59.16%N/ACVRXCVRx-$59.97M-$2.18N/AN/AN/A-116.91%-93.06%-51.78%8/4/2025 (Estimated)LUNGPulmonx-$60.84M-$1.44N/AN/AN/A-67.31%-55.36%-33.53%7/30/2025 (Estimated)ZJYLJin Medical International$3.68MN/A0.00∞N/AN/AN/AN/AN/ALatest AKLI, CVRX, LUNG, and ZJYL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025CVRXCVRx-$0.56-$0.53+$0.03-$0.53$14.68 million$12.35 million5/7/2025Q1 2025LUNGPulmonx-$0.37-$0.36+$0.01-$0.36$22.03 million$22.54 million2/19/2025Q4 2024LUNGPulmonx-$0.45-$0.33+$0.12-$0.33$22.29 million$23.77 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKLIAkiliN/AN/AN/AN/AN/ACVRXCVRxN/AN/AN/AN/AN/ALUNGPulmonxN/AN/AN/AN/AN/AZJYLJin Medical InternationalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKLIAkili0.085.805.80CVRXCVRx0.6912.0610.23LUNGPulmonx0.407.706.77ZJYLJin Medical InternationalN/A2.502.19Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKLIAkili53.12%CVRXCVRx75.27%LUNGPulmonx91.04%ZJYLJin Medical InternationalN/AInsider OwnershipCompanyInsider OwnershipAKLIAkili10.10%CVRXCVRx13.90%LUNGPulmonx6.80%ZJYLJin Medical InternationalN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKLIAkili13078.73 million70.78 millionOptionableCVRXCVRx16026.07 million21.12 millionOptionableLUNGPulmonx25040.26 million37.24 millionOptionableZJYLJin Medical International245156.55 millionN/ANot OptionableAKLI, CVRX, LUNG, and ZJYL HeadlinesRecent News About These CompaniesJin Medical International (NASDAQ:ZJYL) Stock Price Up 5% - Time to Buy?May 8, 2025 | marketbeat.comJin Medical Faces Nasdaq Listing Compliance ChallengeMay 6, 2025 | tipranks.comJin Medical International Ltd. -- Nasdaq Minimum Bid Price Non-ComplianceMay 6, 2025 | gurufocus.comJin Medical International Ltd. – Nasdaq Minimum Bid Price Non-ComplianceMay 6, 2025 | globenewswire.comIs Jin Medical International Ltd.'s (NASDAQ:ZJYL) Recent Stock Performance Influenced By Its Fundamentals In Any Way?April 28, 2025 | finance.yahoo.comJin Medical Boosts Production Capacity with New Chuzhou FacilityApril 25, 2025 | tipranks.comJIN MEDICAL INTERNATIONAL LTD. Ordinary Shares (ZJYL)April 13, 2025 | nasdaq.comWhy Jin Medical International Ltd.’s (ZJYL) Stock Is Down 12.45%April 3, 2025 | aaii.comWhy Jin Medical International Ltd.’s (ZJYL) Stock Is Up 10.09%March 25, 2025 | aaii.comWhy Jin Medical International Ltd.’s (ZJYL) Stock Is Down 29.03%March 22, 2025 | aaii.comWhy Jin Medical International Ltd.’s (ZJYL) Stock Is Up 14.61%March 20, 2025 | aaii.comWhy Jin Medical International Ltd.’s (ZJYL) Stock Is Up 11.29%January 31, 2025 | aaii.comJin Medical International Full Year 2024 Earnings: EPS: US$0.023 (vs US$0.02 in FY 2023)January 27, 2025 | finance.yahoo.comWuhan Jin Jiang International HotelNovember 12, 2024 | travelweekly.comJin of BTS fronts rock band in 'I'll Be There' music videoOctober 25, 2024 | msn.comConstruction of JinMed's New Facility Begins in Chuzhou, ChinaOctober 10, 2024 | globenewswire.comSome Investors May Be Worried About Jin Medical International's (NASDAQ:ZJYL) Returns On CapitalOctober 9, 2024 | finance.yahoo.comZJYL Sees a Stock Surge of 5.04% Amid Positive Financial PerformanceOctober 2, 2024 | gurufocus.comCrude Oil Down Over 1%; US Manufacturing PMI Falls In SeptemberSeptember 24, 2024 | msn.comUnited States shares mixed at close of trade; Dow Jones Industrial Average up 0.09%September 21, 2024 | msn.comU.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.09%September 21, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Why D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumQualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongNVIDIA Stock Surges on Bullish News: How High Could It Climb?By Thomas Hughes | May 13, 2025View NVIDIA Stock Surges on Bullish News: How High Could It Climb?PepsiCo’s Stock Price is Disconnected From Reality: Time to BuyBy Thomas Hughes | April 28, 2025View PepsiCo’s Stock Price is Disconnected From Reality: Time to BuyAKLI, CVRX, LUNG, and ZJYL Company DescriptionsAkili NASDAQ:AKLIAkili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It also offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization. The company was founded in 2011 and is headquartered in Boston, Massachusetts.CVRx NASDAQ:CVRX$6.34 +0.15 (+2.42%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$6.50 +0.16 (+2.52%) As of 05/16/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Pulmonx NASDAQ:LUNG$3.43 +0.01 (+0.29%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$3.43 0.00 (0.00%) As of 05/16/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.Jin Medical International NASDAQ:ZJYL$0.80 -0.03 (-3.38%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$0.78 -0.01 (-1.52%) As of 05/16/2025 06:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Jin Medical International Ltd. engages in the design, development, manufacturing, and sale of wheelchair and other living aids products for people with disabilities or impaired mobility in China and internationally. It also offers oxygen concentrators and bathing machines. The company was founded in 2006 and is based in Changzhou, China. Jin Medical International Ltd. is a subsidiary of Jolly Harmony Enterprises Limited. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/12 - 05/16 Retail Investors Are Betting Big on Rocket Lab—Should You Too? Meta's 5 Key Pillars for AI Growth—Zuckerberg's Bold Vision Taiwan Semiconductor Stock Is The Gift That Keeps on Giving GE Aerospace: Qatar Deal Fuels Multi-Billion Dollar Growth Engine Alibaba's Earnings Just Changed Everything for the Stock Plug Power: Is Q1 Noise An Opportunity for Accumulation? Cisco Stock Eyes New Highs in 2025 on AI, Earnings, Upgrades Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
